

RLL-297US

Claims:

1. (Original): An amorphous form of a salt of esomeprazole.
2. (Currently Amended): The amorphous form of a salt of esomeprazole of claim 1, wherein a cation is selected from the group consisting of Na, Mg, Li, K, Ca, and N(R)<sub>4</sub>, where R is a hydrogen or an alkyl group with 1-4 carbon atoms.
3. (Currently Amended): The amorphous form of a salt of esomeprazole of claim 2, wherein the cation is [comprises] Na.
4. (Currently Amended): The amorphous form of a salt of esomeprazole of claim 2, wherein the cation is [comprises] Mg.
5. (Currently Amended): The amorphous form of a salt of esomeprazole of claim 2, wherein the cation is [comprises] K.
6. (Currently Amended): The amorphous form of a salt of esomeprazole of claim 2, wherein the cation is [comprises] Ca.
7. (Original): The amorphous form of a salt of esomeprazole of claim 1, wherein the esomeprazole salt has the X-ray diffraction pattern of a plain halo.
8. (Cancelled).
9. (Currently Amended): A pharmaceutical composition comprising:  
a therapeutically effective amount of an amorphous form of a salt of esomeprazole;  
and one [andone] or more pharmaceutically acceptable carriers, excipients or diluents.
10. (Original): The pharmaceutical composition of claim 9, wherein a cation is selected from the group consisting of Na, Mg, Li, K, Ca, and N(R)<sub>4</sub>, where R is a hydrogen or an alkyl group with 1-4 carbon atoms.
11. (Currently Amended): The pharmaceutical composition of claim 10, wherein the cation is [comprises] Na.
12. (Currently Amended): The pharmaceutical composition of claim 10, wherein the cation is [comprises] Mg.

RLL-297US

13. (Currently Amended): The pharmaceutical composition of claim 10, wherein the cation is [comprises] K.

14. (Currently Amended): The pharmaceutical composition of claim 10, wherein the cation is [comprises] Ca.

15. (Original): The pharmaceutical composition of claim 10, wherein the esomeprazole salt has the X-ray diffraction pattern of a plain halo.

16. (Cancelled).